Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Novartis India Limited operates as a subsidiary of Novartis AG, focusing on the development and marketing of generic and specialty pharmaceuticals in India. The company benefits from a strong portfolio in therapeutic areas such as cardiology, dermatology, and oncology, leveraging Novartis AG's global R&D capabilities to enhance its competitive position in the Indian market.
Novartis India generates revenue primarily through the sale of generic and specialty drugs, capitalizing on its parent company's extensive R&D and regulatory expertise. The company enjoys pricing power in the Indian market due to its established brand reputation and a diverse product portfolio that addresses unmet medical needs.
Regulatory approvals for new drug launches in India
Market share changes in key therapeutic areas like oncology and cardiology
Pricing adjustments in response to competitive pressures
Currency fluctuations impacting repatriated earnings
Regulatory changes impacting drug pricing and approval processes
Technological disruption in drug development and manufacturing
Increased competition from local and international generic manufacturers
Potential loss of patent protections on key products
Liquidity risk is low due to a strong current ratio of 5.30
Minimal financial risk due to zero debt levels
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but overall consumer spending and healthcare budgets can influence demand.
Minimal sensitivity as the company has zero debt, but rising rates could impact consumer spending on healthcare products.
minimal
value - The strong balance sheet and consistent margins attract value-focused investors.
low - The stock has shown stable historical performance with low beta.
